News Hub | News Direct

All Industries


Article thumbnail News Release

Automated Trading On The Rise As Companies Push Workers Back To The Office

EdgeClear

By Austin DeNoce, Benzinga As the world gradually moves on from the shadow of the pandemic, the corporate drumbeat calling employees back to the office is growing louder. Leading the charge are companies like Goldman Sachs (NYSE: GS) and Alphabet Inc. (NASDAQ: GOOGL), alongside an overwhelming 90% of company leaders who are determined to enforce return-to-office policies by the end of 2024. This shift, driven by concerns about productivity, collaboration and the intangible benefits of in-office work, signals a significant change for employees and traders who've grown accustomed to the flexibility of remote work. Solutions For Traders Returning To The Office If you’re a trader heading back to the office, there are still ways to stay active in the markets without compromising your professional responsibilities. Automated trading strategies are a possible solution, as they enable traders to engage with the markets throughout the day, despite limited screen time. Swing trading also stands out as a time-friendly strategy for traders with busy daily schedules, allowing them to utilize after-hours planning to set market-on-open and market-on-close orders that can be filled while they’re away at work. Both automated and swing trading strategies can accommodate the demands of a full-time job. Since futures trading involves the risk of loss, it should be noted automation can help minimize the emotional pitfalls of trading by leveraging algorithms. Such systems have fully automated alerts and executions, which dramatically reduces the need for market surveillance and enables a more balanced approach to work and trading. Markets won’t adjust to your work schedule, so automation is one way to manage risk and stay on top of trades while your attention is focused on work. How EdgeClear Is Empowering Traders Against the backdrop of return-to-office policies, EdgeClear has positioned itself as a valuable resource for traders seeking to balance their time constraints with their thirst for markets. As a futures broker with an advanced suite of services, EdgeClear offers automated quantitative programs like EdgeQX and EdgeQX-R specifically tailored for intraday futures trading. These programs are designed with the modern trader in mind, incorporating machine learning and diversified signals to facilitate emotion-free trading across E-mini S&P 500 and Micro E-mini S&P 500 contracts. With EdgeClear, traders can enjoy transparency, flexibility in subscription management and access to sophisticated trading algorithms. This blend of features ensures that traders can maintain an active presence in the market, regardless of their return-to-office commitments. Ultimately, these automated services highlight EdgeClear's commitment to aligning trading strategies with the evolving work arrangements of traders. Navigating New Normals The transition back to office work represents a significant shift in the corporate landscape, challenging employees and traders to find new ways of balancing professional commitments with personal and trading activities. However, automated trading strategies, supported by platforms like EdgeClear, offer a viable option for traders to remain active in the markets while adapting to the demands of in-office work schedules. By embracing these tools and strategies, traders can navigate the post-pandemic return-to-office with confidence and without sacrificing their trading. The ability to adapt and leverage technology is itself a powerful edge in trading, making automated services a worthwhile consideration regardless of a trader’s time constraints. However, if you are busy with work, rest assured we live in a world filled with innovative solutions and brokers like EdgeClear allow traders to maintain their presence in markets no matter what occupies their time throughout the day. Featured photo by Maxim Hopman on Unsplash. A forward-thinking futures broker. Led by industry experts who understand the complexities of trading, Edge Clear combines the best of technology, service and risk control. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Max Timmins max@edgeclear.com

April 05, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform

Benzinga

By Jeremy Golden, Benzinga Approximately two million people were diagnosed with cancer in the U.S. in 2023, with breast, prostate, lung and bronchus cancers among the most common. An estimated 609,820 people died of cancer last year. The most common treatments are surgery, chemotherapy and radiation, though other options include targeted therapy as well as laser and hormonal therapies. Another treatment option is immunotherapy, which is designed to utilize the immune system to fight cancer. Immune responses are orchestrated by key immune cells in the lymph nodes, but for many therapies, getting to these critical sites is far from certain. Small molecule-based immunomodulators easily pass through the blood vessel walls at the injection site. As a result, they are rapidly flushed away into the systemic circulation, limiting access to the lymph nodes. Often, this results in a failure to realize the full potential of the immune response. Worse yet, it can lead to the development of dangerous toxicities at other sites in the body. Elicio Therapeutics’ Novel Approach Founded in 2011, Elicio Therapeutics, Inc. (NASDAQ: ELTX) is developing treatment options aimed at significantly improving the quality of life for cancer patients through the utilization of precision vaccines, immunomodulators and cell-based therapies to potentially assemble cancer-killing immune responses against solid tumors. The company is optimistic about the potential of lymph node-targeting made possible by applying the natural trafficking pathways of larger molecules. This approach differentiates Elicio from its competitors and could be highly promising for enhancing anti-tumor immune responses and improving therapeutic efficacy. Developed at the Massachusetts Institute of Technology (MIT), the company’s proprietary Amphiphile or “AMP” platform, which combines expertise in materials science and immunology, is being used to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases. Here’s how it works: The AMP platform is designed to deliver therapeutic payloads directly to critical immune cells in the lymph nodes, enhancing the cancer-fighting mechanisms of the immune system. By delivering cancer immunotherapies to the center of the immune response, this approach is intended to optimize the natural ability of the lymph nodes to educate, activate and amplify cancer-specific T cells. Engineered to coordinate immunity in these uniquely potent sites, the AMP platform was built to amplify the magnitude, potency, quality and durability of the immune response to drive antitumor activity. At the injection site, the platform prevents detrimental payload delivery to systemic circulation, instead guiding the payloads into the lymphatics to promote lymph node delivery. Additionally, it preserves the structural integrity and activity of payloads by preventing any degradation prior to uptake by lymph node resident immune cells. Upon reaching the lymph nodes, the platform optimizes retention and directs the delivery of payloads to key immune cells responsible for the coordination of immune responses, specifically the activation and amplification of cancer-specific immune cells in lymph nodes. Overall, Elicio Therapeutics anticipates that the AMP platform could potentially provide a better quality of life to patients during treatment. The strategy is set apart from other treatments by its ability to activate immune mechanisms directly in the lymph nodes. Enhanced T cell infiltration into tumors, improved T cell expansion and persistence, potent anti-tumor T cell function and wide breadth of response are key attributes with the potential to improve efficacy and reduce the risk of resistance to therapy. Moving forward, Elicio Therapeutics is committed to developing its lymph node-targeting approach for deployment across a range of vaccines, immunomodulators and adjuvants — training the immune system to put the best cells forward to fight a broad spectrum of cancers. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 05, 2024 08:15 AM Eastern Daylight Time

Image
Article thumbnail News Release

FeganScott Announces Lawsuit Against Hyundai and Kia Over Alleged Defect in Certain Hybrid-Electric Vehicles that Poses Serious Safety Risks

FeganScott

FeganScott announces it has filed a class action lawsuit on behalf of Hyundai and Kia vehicle owners and lessees, claiming the automobile manufacturers sold thousands of hybrid-electric vehicles containing a defect that poses serious safety risks to drivers and passengers. The lawsuit revolves around a defect in the engine clutch actuator (ECA), sometimes called the hydraulic clutch actuator. The vehicles named in the suit include 2017-2022 Kia Niro Hybrid, 2018-2022 Kia Niro Plug-In Hybrid, and 2017-2022 Hyundai Ioniq Hybrid vehicles. According to the complaint filed in the U.S. District Court for the Central District of California, the defect allows fluid to leak into the engine clutch actuator, which can cause the car to stall and, in some reported instances, start a vehicle fire. In July 2023, Kia issued a safety recall for certain Niro Hybrid vehicles due to the alleged ECA defect. However, the lawsuit states that the recall failed to fix the root cause of the defect, and that it does not prevent the risk of stalled vehicles. The suit also notes that Hyundai installed the same ECA component in its Hyundai Ioniq Hybrid vehicles and has not issued a safety recall. “Hyundai and Kia have a long history of failing to issue timely and complete fixes for known defects in their vehicles, and this latest defect with the engine clutch actuator in certain hybrid-electric models is no different,” said FeganScott attorney Jonathan Lindenfeld. “Our firm has devoted significant time and resources to ensure that the largest automobile manufacturers in the world live up to their responsibilities. Consumers who spend tens of thousands of dollars for their vehicles deserve products that are safe and reliable.” Drivers of the affected vehicles are encouraged to send their contact information to autosafety@feganscott.com to learn more about their rights. # # # Case No. 8:24-cv-00731 About FeganScott FeganScott is a national class action law firm dedicated to helping victims of consumer fraud, sexual abuse, and discrimination. The firm is championed by acclaimed veteran class action attorneys who have successfully recovered $1 billion for victims nationwide. FeganScott is committed to pursuing successful outcomes with integrity and excellence while holding the responsible parties accountable. Contact Details Mark Firmani +1 206-466-2700 feganscottpr@firmani.com Company Website https://feganscott.com

April 05, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Platinum Learning Nursing CE Announces Continuing Education Programs for Healthcare Professionals

Rev Up Marketers

Platinum Learning Nursing CE, a provider of continuing education (CE) for healthcare professionals, has announced a new lineup of programs designed to meet the educational needs of registered nurses (RNs), licensed vocational nurses (LVNs), licensed psychiatric technicians (LPTs), and advanced practice registered nurses (APRNs). These programs cover a wide range of topics essential for maintaining competency and staying up-to-date with the latest advancements in healthcare. Focus on Registered Nurses (RNs) Registered nurses play a vital role in the healthcare system, providing care to patients in various settings. To maintain their licensure, RNs in most states, including California, are required to complete a certain number of CE credits every renewal period as mandated by the California Board of Registered Nursing (BRN). When searching for RN license renewal CE providers, Platinum Learning Nursing CE stands out with its comprehensive curriculum and engaging learning formats. Their CE programs for RNs address a variety of relevant subjects, including: Medical-Surgical Nursing Critical Care Nursing Pediatric Nursing Geriatric Nursing Mental Health Nursing Leadership and Management Legal and Ethical Issues in Nursing The programs are designed to be informative and engaging, featuring interactive modules, case studies, and self-assessments to reinforce learning. Addressing LVN License Renewal in California Licensed vocational nurses (LVNs) are an essential part of the healthcare team, working under the supervision of RNs and physicians to provide direct patient care. In California, LVNs are mandated to complete 30 CE hours for each license renewal cycle. The company offers a comprehensive selection of CE programs specifically tailored to the needs of LVNs in California, encompassing topics directly relevant to LVN license renewal in California, such as: Basic Nursing Skills Medication Administration Wound Care Infection Control Communication and Collaboration Documentation and Reporting These programs are developed to ensure LVNs meet the California Board of Vocational Nursing and Psychiatric Technicians (BVNPT) requirements for license renewal. Continuing Education Opportunities for Other Healthcare Professionals The company also caters to the educational needs of licensed psychiatric technicians (LPTs) and advanced practice registered nurses (APRNs). LPT programs address mental health assessment, crisis intervention, and psychopharmacology, while APRN programs delve into areas like primary care, family practice, and acute care. Conclusion Platinum Learning Nursing CE's commitment to providing high-quality, accessible CE programs empowers healthcare professionals across various disciplines to enhance their knowledge, skills, and abilities. This focus on continuing education fosters better patient care, improved healthcare outcomes, and a more competent healthcare workforce. For any press-related queries or additional details, please mail to support@platinumlearningce.org or visit https://www.platinumlearningce.org/. About Platinum Learning Nursing CE Platinum Learning Nursing CE is a dedicated provider of continuing education programs for healthcare professionals, including registered nurses, licensed vocational nurses, licensed psychiatric technicians, and advanced practice registered nurses. Their mission is to empower nurses and other healthcare providers with the knowledge and skills necessary to deliver exceptional patient care. Their programs are developed by industry experts and adhere to the latest guidelines and regulations set forth by regulatory bodies. Contact Details Platinum Learning Nursing CE Irine Achuamang +1 424-347-0362 info@platinumlearningce.org Company Website https://www.platinumlearningce.org/

April 04, 2024 05:31 PM Eastern Daylight Time

Image
Article thumbnail News Release

Benchmark International Has Successfully Facilitated The Transaction Of Plant Drives & Systems To Aes, Inc.

Benchmark International

Plant Drives & Systems, specializing in systems integration for variable-frequency drives and automated systems, is pleased to announce its acquisition by AES, Inc., an esteemed industrial equipment solutions provider. Plant Drives & Systems, based in Chattanooga, TN, specializes in systems integration for variable-frequency drives and automated systems. Since 2010, the company has prioritized delivering high-quality service to its customers. The acquisition will help grow the current facility and expand their service geographically. AES, Inc., established in 1992, is a renowned industrial equipment solutions provider based in Mount Airy, NC. With over 120+ employees, it is a powerhouse providing industrial electronic, hydraulic, and mechanical equipment repair services and new and used equipment sales. Its impeccable reputation is a testament to its commitment to quality, and it is thrilled to welcome Plant Drives & Systems into its fold. “This is an exciting time for Plant Drives & Systems and AES. As one unified team, we will become an even stronger service provider within our industry.”—Nicholas Cooke, CEO, AES, Inc. “To echo Mr. Cooke, joining these two companies will enable them to service their customers better and become an incredible force in their respective industries. This is what we strive for when representing our clients. Congratulations to all.”– Senior Director Matthew Kekelis, Benchmark International Americas: Sam Smoot at +1 (813) 898 2350 / Smoot@BenchmarkIntl.com Europe: Michael Lawrie at +44 (0) 161 359 4400 / Lawrie@BenchmarkIntl.com Africa: Anthony McCardle at +27 21 300 2055 / McCardle@BenchmarkIntl.com ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

April 04, 2024 05:23 PM Eastern Daylight Time

Image
Article thumbnail News Release

Investors Rush to New Crypto Presale Raboo (RABT) as Pepe (PEPE) & Shiba Inu (SHIB) See Modest Gains

Total Media

Presales and ICOs are where the smart money shops for the next meme coin to explode. Any investor worth their gains knows that a new crypto presale is not something to be overlooked, as coins like Pepe and Shiba Inu have proven time and time again. Now, there’s a new crypto presale in town: Raboo. Available in stage 1 for only $0.003, this coin is setting the world alight with a 233% growth during the presale phase and an explosive 100x expected once it hits the markets. It’s not hot air; it has happened before. Pepe (PEPE): Stratospheric Gains See Slight Retraction Pepe sits in the top 5 cryptos with an enormous market cap of just a shade under $3 billion. But what is truly amazing is that Pepe’s price has grown… wait for it… 66 million percent in the last year. This is a figure easily verified on any market tracker. To imagine what a $1.00 investment in Pepe a year ago could have been worth today is the stuff fairy tales and movies are made of. Over the last 30 days, Pepe has not been quite as ambitious, and it only saw a raise of close to 30%. It even recorded a slight loss over the last week as profit-takers laugh all the way to the Lambo dealership. Pepe’s exponential growth may be behind it, but this does not mean it cannot be repeated. There’s money in meme coins, and the new crypto presale of Raboo may just be the next million-percenter. Shiba Inu (SHIB): Still Barking Up the Right Tree When Shiba Inu popped onto the scene, it was dismissed as a worthless rip-off. And then Shiba Inu proved all its critics wrong by returning yields so high that the math became absurd. Billionaires were made in less than a year as Shiba Inu dropped zero after zero beyond the decimal point to gain a market cap of over $15.5 billion. Last year, Shiba Inu stunned the markets with a 140% gain. Shiba Inu is also suffering a bit of a profit-taking downturn for a negative candle over the last seven days, but all indicators show that the meme coins are where the smart money goes not just to grow but to go absolutely nuclear. Raboo (RABT): The New Crypto Presale Set To Explode The next meme coin to explode may be Raboo, which is now in presale. Raboo is winning hearts and minds with its innovative narrative: it’s on a mission to rid the world of useless memes that only want to ride the coattails of the great ones without adding anything of value. Raboo will fix that! The presale is underway, and investors are already hunting Raboo tokens while the going is still good. The first spike in price will happen too soon, and then the dreaded FOMO feeling will settle in, and nobody wants that. Conclusion: As Pepe and Shiba Inu have proven, meme coins are not to be trifled with. Raboo’s new crypto presale is nicely set up to mark it as the next meme coin to explode, bringing joy and profit to all investors. You can participate in the Raboo presale here. Contact Details Total Media Solutions media@Totalsolutionspr.io

April 04, 2024 04:04 PM Eastern Daylight Time

Image
Article thumbnail News Release

Allied Corp Completes 80kg Shipment to European Channel Partner Coinciding with German Decriminalization Act

Allied Corp.

Kelowna, BC, Canada – TheNewswire – April 4, 2024 Allied Corp. ("Allied" or the “Company”) ( OTCQB: ALID ) is pleased to announce that it has successfully completed an 80kg export of THC-based medical cannabis to one of its GMP (Good Manufacturing Practices) manufacturing partners in Europe. The shipment has cleared customs. Through its partner, Allied will offer to the European market flower and derivatives manufactured with GMP certification – a key requirement for import into several countries, including Germany.   This comes at a time when the European medical cannabis market received a significant boost with the German Cannabis Decriminalization Act (Pillar 1) which came into effect on 1 April 2024. Under the Act, cannabis has been officially removed from Germany’s Narcotics List which is expected to drastically improve patient access and support further adoption of medical cannabis. Patients will no longer require a narcotic prescription form, which experts say will simplify the process for doctors and streamline the medical cannabis supply chain. The legislation also allows adults to possess up to 25g for personal use and cultivate up to three plants for private consumption, while paving the way for wider recreational legalization.   " With this shipment and its established European channel partnerships, Allied is set to play a key role in rapidly expanding markets, including Germany”, said Juba Hadid, VP of Global Sales. “This also solidifies the particular attractiveness of Allied’s offering to international buyers: high quality at a low cost.”   Allied has once again demonstrated its ability to export Colombian flower. This shipment follows the recent 180kg purchase order (press release here ), two international flower distribution agreements signed earlier this year (press releases here and here ) and two successful shipments of THC-based medical cannabis to Australia in November 2023 (press releases here and here ).   About Allied Corp. – CLICK HERE Allied Corp.  is a Canadian cannabis supplier with its production center in Colombia. By leveraging Canadian cannabis cultivation expertise and Colombian price advantages, Allied offers consistent supply of premium cannabis product at scale and at attractive prices, while meeting international high-quality standards. Investor Relations: ir@allied.health 1-877-255-4337 Forward-Looking Statements: This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or the United States ( “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and the introduction of TACTICAL RELIEF™ branded products. There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company's continuous disclosure including its Management's Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company's profile at www.sec.gov. Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

April 04, 2024 03:00 PM Eastern Daylight Time

Article thumbnail News Release

Annette Clayton Joins Flash Board of Directors

Flash Parking

Flash, the leading digital ecosystem provider connecting drivers to parking and EV charging experiences, today announced Annette Clayton, chairwoman and former CEO of Schneider Electric, has joined the company’s board of directors. Ms. Clayton has decades of automotive, technology and energy industry experience and brings an extensive track record guiding corporate strategy and operations for growth companies and pioneering startups. “We are incredibly fortunate to welcome Annette to our board of directors,” said Dan Sharplin, Flash’s CEO and Chairman. “She is an accomplished leader who has dedicated her career to companies that are transforming their respective industries, and her talents and expertise will be invaluable to our next chapter of growth, particularly when it comes to meeting the needs of modern drivers through the next wave of EV adoption.” Ms. Clayton joins Flash’s board of directors after recently concluding her tenure as CEO of Schneider Electric North America. During that time, Ms. Clayton led business strategy for the region, representing 30,000 employees and sales of more than $11 billion in fiscal year 2022. “Working with innovators like Flash that reimagine an industry is the work I love,” said Ms. Clayton regarding her appointment. “I have followed Flash’s evolution from its startup days and think the current moment is among its most exciting – Flash has done the heavy lifting and is poised to bring all the players together to set the new standard for a first-of-its-kind digital ecosystem.” Ms. Clayton currently serves on the public boards of Duke Energy, NXP Semiconductors, Oshkosh Corporation and Nordson Corporation. Ms. Clayton’s prior board service includes National Electrical Manufacturers Association, National Association of Manufacturers and many of Schneider Electric’s Energy-as-a-Service joint ventures. She was also a member of Rewiring America’s CEO’s for Electrification coalition for business leaders. Prior to Schneider Electric, she served in senior management roles for Dell, where she led the transformation of its global supply chain and fulfillment model, and General Motors Corporation, including president of Saturn Corporation, where she oversaw strategic direction, financial accountability, and profitability. Ms. Clayton holds a bachelor’s degree in general engineering from Wright State University, a master’s degree in engineering management from the University of Dayton and has completed the London Business School executive development program. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Flash Parking Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

April 04, 2024 03:00 PM Eastern Daylight Time

Article thumbnail News Release

Kingston Resources raising $13.5 million to accelerate long-term critical minerals vision

KINGSTON RESOURCES LIMITED

Kingston Resources Ltd (ASX:KSN) CEO Andrew Corbett sits down with Proactive’s Jonathan Jackson to discuss a $13.5 million capital raise, of which $8.1 million has been raised and another $5.4 million is expected through an accelerated non-renounceable entitlement offer (ANERO). The money will go to expanding the Pearse Project and completing the Tailings Mining Project at the Mineral Hill operations. The funds are earmarked for boosting production and supporting operational enhancements. Corbett highlights the strategic significance of these projects in central New South Wales, noting an expected 133% increase in payable metal year-on-year and the completion of the Tailings Project, which paves the way for hard rock mining at Mineral Hill. With the processing plant's refurbishment nearly finished, Kingston Resources is poised for a significant production ramp-up, solidifying its strategic position in the resource-rich Cobar region. Corbett's vision extends to establishing a sustainable, long-term critical minerals operation, capitalising on the company’s robust infrastructure and exploration potential. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 jonathan@proactiveinvestors.com

April 04, 2024 01:15 PM Eastern Daylight Time

Video
1 ... 273274275276277 ... 3738